Dailypharm Live Search Close

The MOHW expressed reluctance to Keytruda's primary benefit

By Lee, Jeong-Hwan | translator Choi HeeYoung

21.10.06 17:48:43

°¡³ª´Ù¶ó 0
It is difficult to manage drug prices even in the evaluation system

The patient is under a lot of pressure

 ¡ã Minister Kwon Deok-cheol (photo = provided by the National Assembly

Minister of Health and Welfare Kwon Deok-cheol expressed reluctance to applying MSD immuno-cancer drug Keytruda as a primary treatment for lung cancer, citing enormous health insurance financial needs.

On the 6th, Minister Kwon responded to a question from Kang Sun-woo (the Democratic Party of Korea) at the National Assembly Welfare Committee's parliamentary audit. He pointed out that when lung cancer was first treated with Keytruda, it was more effective in treating diseases than when used as a secondary treatment. He introduced that the U.S. NCC guidelines also recommend Keytruda as a priority in single and combined therapy. He criticized that unlike overseas countries such as the United States, Korea

Lee, Jeong-Hwan(junghwanss@dailypharm.com)
If you want to see the full article, please JOIN US (click)